Abstract: In a demand level calculation apparatus (20) of the present invention, the advertisement information acquisition unit (21) acquires advertisement information on at least one of an advertising target product or an advertising target service in a specific area of a real space, the coordinate information generation unit (22) generates coordinate information associated with a fiducial marker installed in the specific area, and maps a virtual point indicating a specific position in the specific area on the coordinate information, and associates the virtual point with the advertisement information, the visitor information acquisition unit (23) acquires visitor information including attribute information and behavior information of a visitor in the specific area, and the demand level calculation unit (24) calculates a magnitude of a demand level for the advertisement information based on the advertisement information and the visitor information.

Abstract: In an advertisement information generation apparatus (30) of the present invention, the advertisement information generation unit (31) generates advertisement information on at least one of an advertising target product or an advertising target service, the coordinate information acquisition unit (32) acquires coordinate information associated with a fiducial marker installed in a specific area of a real space, a virtual point indicating a specific position in the specific area is mapped on the coordinate information, the virtual object generation unit (33) generates a virtual object associated with the virtual point and the advertisement information, the virtual object is composed of a main object and a sub object, the main object is an image object representing contents of the advertisement information, and the sub object is an object to which text information representing the contents of the advertisement information is added.

Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.

Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.

Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.

Abstract: A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.

Abstract: A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.

Abstract: An aspartic enzyme having a high homology with a cathepsin D precursor, which is a protein having the N-terminal amino acid sequence LVRIPLHKFT (SEQ ID NO: 1) and showing a molecular weight of about 45 kDa in non-reductive SDS electrophoresis and can degrade plasma proteins, typically plasminogen, to produce plasma protein fragments having an inhibitory activity to metastasis and growth of cancer; the plasma protein fragments having an inhibitory activity to metastasis and growth of cancer which is prepared via the degradation with the above enzyme; a process for preparing the protein fragments which comprises degrading plasma proteins with the above enzyme; and a medicament for treating and preventing metastasis and growth of cancer which comprises as a major ingredient the above enzyme or the plasma protein fragments.

Abstract: The present invention provides a plasminogen fragment with the activity to inhibit tumor metastasis and growth, a process for preparing said fragment and an agent for inhibiting tumor metastasis and growth comprising said fragment as an active ingredient. The plasminogen fragment of the present invention is prepared from a elastase lysate of Lys-Plasminogen, which is produced by treating a natural plasminogen with plasmin, and preferably exhibits a strong heparin binding activity. The agent for inhibiting tumor metastasis and growth comprising the plasminogen fragment as an active ingredient of the present invention is useful for clinically treating solid cancers such as lung cancer or colon cancer.

Abstract: The present invention provides a plasminogen fragment with the activity to inhibit tumor metastasis and growth, a process for preparing said fragment and an agent for inhibiting tumor metastasis and growth comprising said fragment as an active ingredient. The plasminogen fragment of the present invention is prepared from a elastase lysate of Lys-Plasminogen, which is produced by treating a natural plasminogen with plasmin, and preferably exhibits a strong heparin binding activity. The agent for inhibiting tumor metastasis and growth comprising the plasminogen fragment as an active ingredient of the present invention is useful for clinically treating solid cancers such as lung cancer or colon cancer.